<DOC>
	<DOCNO>NCT01966458</DOCNO>
	<brief_summary>This prospective , randomize , control , unblinded , multi-center evaluation stroke incidence patient implant HeartWare® HVAD receive optimal blood pressure management . The study compare result stroke incidence new cohort subject receive optimal blood pressure management reference stroke incidence observe original IDE clinical trial ( HW004 ) specify optimal blood pressure management . In addition , secondary endpoint evaluate non-inferiority stroke-free success originally implant device control group ( i.e . FDA-approved LVAD destination therapy ) . Subjects randomize HeartWare® HVAD control LVAD 2:1 ratio . Each subject receive HeartWare® HVAD control LVAD follow primary secondary endpoint 12 month , subsequent follow-up period extend 5 year post implant .</brief_summary>
	<brief_title>A Clinical Trial Evaluate HeartWare® Ventricular Assist System ( ENDURANCE SUPPLEMENTAL TRIAL )</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Must ≥18 year age consent 2 . Body Surface Area ( BSA ) ≥ 1.2 m2 3 . Patients advanced heart failure symptom ( Class IIIB IV ) : ( patient must meet one follow ) . On optimal medical management , include dietary salt restriction diuretic , least 45 last 60 day fail respond ; b . In Class III Class IV heart failure least 14 day , dependent intraaortic balloon pump ( IABP ) 7 day and/or inotropes least 14 day 4 . Left ventricular ejection fraction ≤ 25 % 5 . LVAD implant intend destination therapy 6 . Must able receive either HeartWare® HVAD control LVAD 7 . Patient must agree participate comply improved blood pressure management program , include maintenance patient diary . 8 . Female patient childbearing potential must agree use adequate contraceptive precaution ( defined oral contraceptive , intrauterine device , surgical contraceptive combination condom spermicide ) duration study . 9 . The patient legally authorize representative sign informed consent form 1 . Body Mass Index ( BMI ) &gt; 40 2 . Existence ongoing mechanical circulatory support ( MCS ) intraaortic balloon pump ( IABP ) 3 . Prior cardiac transplant . 4 . History confirm , untreated abdominal thoracic aortic aneurysm &gt; 5 cm . 5 . Cardiothoracic surgery within 30 day randomization . 6 . Acute myocardial infarction within 14 day implant diagnosed ST T wave change ECG , diagnostic biomarkers , ongoing pain hemodynamic abnormality describe ( Figure 2 ) guideline publish ACC/AHA 2007 Guidelines Management Patients Unstable Angina/NonSTElevation Myocardial Infarction ; . 7 . Patients eligible cardiac transplantation 8 . On ventilator support &gt; 72 hour within four day immediately prior randomization implant . 9 . Pulmonary embolus within three week randomization document computed tomography ( CT ) scan nuclear scan . 10 . Symptomatic cerebrovascular disease , stroke within 180 day randomization &gt; 80 % stenosis carotid cranial vessel . 11 . Uncorrected moderate severe aortic insufficiency . Correction may include repair bioprosthesis time implant . 12 . Severe right ventricular failure define anticipate need right ventricular assist device ( RVAD ) support extracorporeal membrane oxygenation ( ECMO ) time screening/randomization right atrial pressure &gt; 20 mmHg multiple inotropes right ventricular ejection fraction ( RVEF ) &lt; 15 % clinical sign severe right heart failure ( e.g . Lower extremity edema , ascites pleural effusion refractory treatment diuretic two inotropic drug ) . 13 . Active , uncontrolled infection diagnose combination clinical symptom laboratory testing , include limited , continue positive culture , elevated temperature white blood cell ( WBC ) count , hypotension , tachycardia , generalize malaise despite appropriate antibiotic , antiviral antifungal treatment . 14 . Uncorrected thrombocytopenia generalize coagulopathy ( e.g. , platelet count &lt; 75,000 , INR &gt; 2.0 PTT &gt; 2.5 time control absence anticoagulation therapy ) . 15 . Intolerance anticoagulant antiplatelet therapy peri postoperative therapy investigator may administer base upon patient 's health status . 16 . Serum creatinine &gt; 3.0 mg/dL within 72 hour randomization require dialysis ultrafiltration . 17 . Specific liver enzymes [ AST ( SGOT ) ALT ( SGPT ] &gt; 3 time upper limit normal within 72 hour randomization . 18 . A total bilirubin &gt; 3 mg/dl within 72 hour randomization , biopsy proven liver cirrhosis portal hypertension . 19 . Pulmonary vascular resistance demonstrate unresponsive pharmacological manipulation PVR &gt; 6 Wood unit . 20 . Patients mechanical heart valve . 21 . Etiology heart failure due , associate , uncorrected thyroid disease , obstructive cardiomyopathy , pericardial disease , amyloidosis , active myocarditis restrictive cardiomyopathy 22 . History severe COPD severe restrictive lung disease ( e.g . FEV1 &lt; 50 % ) 23 . Participation study involve investigational drug device 24 . Severe illness , heart disease , would limit survival &lt; 3 year 25 . Peripheral vascular disease rest pain ischemic ulcer extremities 26 . Pregnancy 27 . Patient unwilling unable comply study requirement 28 . Technical obstacle , pose inordinately high surgical risk , judgment investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>